Cargando…

Predictable Resistance and Overall Survival of Gemcitabine/Cisplatin by Platelet Activation Index in Non-Small Cell Lung Cancer

BACKGROUND: Gemcitabine/cisplatin (GP) resistance displays a negative role in treating advanced and metastatic non-small cell lung cancer (NSCLC). Several studies found that the association existed between platelets and cancer antigen 125 (CA125) with anticancer drugs. But the exact correlation betw...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Liang, Li, Yiming, Yu, Tingting, Wang, Zeng, Zhou, Chenxi, Xing, Wenxiu, Xu, Gaoqi, Tong, BingLei, Zheng, Yingchao, Zhou, Jie, Huang, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284361/
https://www.ncbi.nlm.nih.gov/pubmed/30498189
http://dx.doi.org/10.12659/MSM.911125
_version_ 1783379320833572864
author Shi, Liang
Li, Yiming
Yu, Tingting
Wang, Zeng
Zhou, Chenxi
Xing, Wenxiu
Xu, Gaoqi
Tong, BingLei
Zheng, Yingchao
Zhou, Jie
Huang, Ping
author_facet Shi, Liang
Li, Yiming
Yu, Tingting
Wang, Zeng
Zhou, Chenxi
Xing, Wenxiu
Xu, Gaoqi
Tong, BingLei
Zheng, Yingchao
Zhou, Jie
Huang, Ping
author_sort Shi, Liang
collection PubMed
description BACKGROUND: Gemcitabine/cisplatin (GP) resistance displays a negative role in treating advanced and metastatic non-small cell lung cancer (NSCLC). Several studies found that the association existed between platelets and cancer antigen 125 (CA125) with anticancer drugs. But the exact correlation between GP resistance and platelet activation index remains poorly understood. MATERIAL/METHODS: Pre-chemotherapy platelet activation index and CA125 were retrospectively evaluated in 169 advanced and metastatic NSCLC patients. All variables were screened by chi-square test and then evaluated by log-rank test. Survival curves were generated by Kaplan-Meier analysis. Univariate and multivariate survival analysis were performed by using Cox proportional hazards model. RESULTS: The overall rate of GP resistance for NSCLC patients was 72.19%. Mean platelet volume (MPV) and plateletcrit (PCT) are negative predictors of GP resistance adenocarcinoma [Odds ratio (OR): 5.81, 95% confidence interval (CI): 1.082–31.195, P=0.004] and squamous cell carcinoma (PCT: R: 3.517, 95% CI: 1.087–11.387, P=0.036), respectively. But both were an independent factor associated with overall survival (OS). Moreover, only CA125 was a dependent factor associated with OS for squamous cell carcinoma [OS: hazard ratio (HR): 1.741, 95% CI: 1.002–3.024, P=0.049; GP resistance: OR: 4.862, 95% CI: 1.437–16.448, P=0.011]. CONCLUSIONS: Platelet activation index will be a potential marker for predicting GP resistance. Besides, CA125 ≥16.9 could be used as a potential marker for predicting GP resistance and OS, which was more sensitive than CA125 ≥35 for squamous cell carcinoma.
format Online
Article
Text
id pubmed-6284361
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-62843612018-12-28 Predictable Resistance and Overall Survival of Gemcitabine/Cisplatin by Platelet Activation Index in Non-Small Cell Lung Cancer Shi, Liang Li, Yiming Yu, Tingting Wang, Zeng Zhou, Chenxi Xing, Wenxiu Xu, Gaoqi Tong, BingLei Zheng, Yingchao Zhou, Jie Huang, Ping Med Sci Monit Clinical Research BACKGROUND: Gemcitabine/cisplatin (GP) resistance displays a negative role in treating advanced and metastatic non-small cell lung cancer (NSCLC). Several studies found that the association existed between platelets and cancer antigen 125 (CA125) with anticancer drugs. But the exact correlation between GP resistance and platelet activation index remains poorly understood. MATERIAL/METHODS: Pre-chemotherapy platelet activation index and CA125 were retrospectively evaluated in 169 advanced and metastatic NSCLC patients. All variables were screened by chi-square test and then evaluated by log-rank test. Survival curves were generated by Kaplan-Meier analysis. Univariate and multivariate survival analysis were performed by using Cox proportional hazards model. RESULTS: The overall rate of GP resistance for NSCLC patients was 72.19%. Mean platelet volume (MPV) and plateletcrit (PCT) are negative predictors of GP resistance adenocarcinoma [Odds ratio (OR): 5.81, 95% confidence interval (CI): 1.082–31.195, P=0.004] and squamous cell carcinoma (PCT: R: 3.517, 95% CI: 1.087–11.387, P=0.036), respectively. But both were an independent factor associated with overall survival (OS). Moreover, only CA125 was a dependent factor associated with OS for squamous cell carcinoma [OS: hazard ratio (HR): 1.741, 95% CI: 1.002–3.024, P=0.049; GP resistance: OR: 4.862, 95% CI: 1.437–16.448, P=0.011]. CONCLUSIONS: Platelet activation index will be a potential marker for predicting GP resistance. Besides, CA125 ≥16.9 could be used as a potential marker for predicting GP resistance and OS, which was more sensitive than CA125 ≥35 for squamous cell carcinoma. International Scientific Literature, Inc. 2018-11-30 /pmc/articles/PMC6284361/ /pubmed/30498189 http://dx.doi.org/10.12659/MSM.911125 Text en © Med Sci Monit, 2018 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Clinical Research
Shi, Liang
Li, Yiming
Yu, Tingting
Wang, Zeng
Zhou, Chenxi
Xing, Wenxiu
Xu, Gaoqi
Tong, BingLei
Zheng, Yingchao
Zhou, Jie
Huang, Ping
Predictable Resistance and Overall Survival of Gemcitabine/Cisplatin by Platelet Activation Index in Non-Small Cell Lung Cancer
title Predictable Resistance and Overall Survival of Gemcitabine/Cisplatin by Platelet Activation Index in Non-Small Cell Lung Cancer
title_full Predictable Resistance and Overall Survival of Gemcitabine/Cisplatin by Platelet Activation Index in Non-Small Cell Lung Cancer
title_fullStr Predictable Resistance and Overall Survival of Gemcitabine/Cisplatin by Platelet Activation Index in Non-Small Cell Lung Cancer
title_full_unstemmed Predictable Resistance and Overall Survival of Gemcitabine/Cisplatin by Platelet Activation Index in Non-Small Cell Lung Cancer
title_short Predictable Resistance and Overall Survival of Gemcitabine/Cisplatin by Platelet Activation Index in Non-Small Cell Lung Cancer
title_sort predictable resistance and overall survival of gemcitabine/cisplatin by platelet activation index in non-small cell lung cancer
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284361/
https://www.ncbi.nlm.nih.gov/pubmed/30498189
http://dx.doi.org/10.12659/MSM.911125
work_keys_str_mv AT shiliang predictableresistanceandoverallsurvivalofgemcitabinecisplatinbyplateletactivationindexinnonsmallcelllungcancer
AT liyiming predictableresistanceandoverallsurvivalofgemcitabinecisplatinbyplateletactivationindexinnonsmallcelllungcancer
AT yutingting predictableresistanceandoverallsurvivalofgemcitabinecisplatinbyplateletactivationindexinnonsmallcelllungcancer
AT wangzeng predictableresistanceandoverallsurvivalofgemcitabinecisplatinbyplateletactivationindexinnonsmallcelllungcancer
AT zhouchenxi predictableresistanceandoverallsurvivalofgemcitabinecisplatinbyplateletactivationindexinnonsmallcelllungcancer
AT xingwenxiu predictableresistanceandoverallsurvivalofgemcitabinecisplatinbyplateletactivationindexinnonsmallcelllungcancer
AT xugaoqi predictableresistanceandoverallsurvivalofgemcitabinecisplatinbyplateletactivationindexinnonsmallcelllungcancer
AT tongbinglei predictableresistanceandoverallsurvivalofgemcitabinecisplatinbyplateletactivationindexinnonsmallcelllungcancer
AT zhengyingchao predictableresistanceandoverallsurvivalofgemcitabinecisplatinbyplateletactivationindexinnonsmallcelllungcancer
AT zhoujie predictableresistanceandoverallsurvivalofgemcitabinecisplatinbyplateletactivationindexinnonsmallcelllungcancer
AT huangping predictableresistanceandoverallsurvivalofgemcitabinecisplatinbyplateletactivationindexinnonsmallcelllungcancer